Financial Performance - As of March 31, 2025, cash, cash equivalents, and restricted cash totaled approximately $1.8 million[7] - Research and development expenditures for Q1 2025 were $1.3 million, up from $1.0 million in Q1 2024, representing a 30% increase[7] - General and administrative expenses for Q1 2025 were approximately $1.8 million, compared to approximately $1.5 million in Q1 2024, reflecting a 20% increase[7] - The net loss for Q1 2025 was approximately $2.9 million, an improvement from a net loss of approximately $3.4 million in Q1 2024, indicating a 15% reduction in losses[7] - Net loss per share for Q1 2025 was $0.45, compared to $0.75 for Q1 2024, showing a 40% improvement[7] Clinical Trials and Research - The planned Phase 3b clinical trial for NurOwn is designed to enroll approximately 200 early-stage ALS participants[3] - An IND amendment for NurOwn has been submitted to the FDA, marking a significant milestone for the upcoming Phase 3b trial[3] - NurOwn data was selected for presentation at the ISCT 2025 Meeting, highlighting the impact of the UNC13A genotype on clinical outcomes for ALS patients[3] Assets and Liabilities - Total assets as of March 31, 2025, were $3.571 million, compared to $1.832 million as of December 31, 2024, indicating a significant increase[15] - Total liabilities as of March 31, 2025, were $11.028 million, up from $9.596 million as of December 31, 2024[15]

Financial Position - As of June 30, 2023, total assets amounted to $19,364,203,757, with total current assets at $334,054,275 and total non-current assets at $19,030,149,482[24]. - Total current liabilities were reported at $3,940,346,398, while total non-current liabilities reached $7,013,873,839, resulting in total liabilities of $10,954,220,237[26]. - The equity of the company stood at $8,409,983,520, which includes common stock valued at $2,958,456,458 and accumulated losses of $(3,537,549,796)[26]. Shareholder Information - As of March 21, 2024, the company had 79,242,873 ordinary shares outstanding, with Elias Sacal Cababie holding 87.2% of the shares[46]. - The company has a significant concentration of ownership, with the top two shareholders holding a combined 98.2% of the ordinary shares[46]. Company Structure and Governance - The company was incorporated on July 27, 2023, and transitioned to a public limited company on March 1, 2024[29]. - The principal executive office of the company is located at 25 Berkeley Square, London W1J 6HN[29]. - The independent registered public accounting firm for the company is KPMG Cárdenas Dosál, S.C.[22]. - The Chief Financial Officer, David Galan, has signed the report, reflecting corporate governance and accountability[81]. Financial Reporting and Compliance - The company is subject to certain informational filing requirements of the Exchange Act as a foreign private issuer[31]. - Murano's audited combined financial statements for the years ended December 31, 2021 and 2022 are incorporated by reference, showing significant financial performance[73]. - Unaudited interim condensed combined financial statements for the six months ended June 30, 2023, indicate a comparison with the same period in 2022[73]. - The company is subject to the informational filing requirements of the Exchange Act as a foreign private issuer, impacting its reporting frequency[65]. - Murano's financial statements are audited by an independent accounting firm, ensuring compliance and accuracy in financial reporting[73]. - The registrant confirms compliance with all requirements for filing on Form 20-F, indicating adherence to regulatory standards[80]. Market Presence - The company’s ordinary shares and warrants are listed on Nasdaq under the symbols "MRNO" and "MRNOW" respectively[52]. - Murano's ordinary shares and warrants are quoted on Nasdaq, providing liquidity and market visibility[66]. - The company maintains a website for additional information, although it is not incorporated into the official reports[66]. Financial Agreements and Partnerships - The company has entered into various loan agreements, including a U.S. dollar-denominated syndicated secured mortgage loan agreement dated October 4, 2019[76]. - The company has executed a third amendment to a peso-denominated loan agreement with Banco Nacional de Comercio Exterior, dated December 11, 2023[78]. - A memorandum of understanding was established on March 30, 2023, involving multiple hotel operators, indicating potential collaboration or strategic partnerships[78]. - The company has made several amendments to counter guarantees, with the latest being executed on August 22, 2023, suggesting ongoing financial restructuring or support mechanisms[78]. - The company has undergone business combination agreements, indicating strategic growth initiatives and potential market expansion[76]. Financial Projections - The unaudited pro forma condensed combined financial statements of Murano are attached as Exhibit 15.1, providing insights into financial projections[75].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-42506 CALLAN JMB INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40591 HCW Biologics Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-5024477 (State or other jurisdictio ...

Exhibit 99.1 Business Highlights to Date: ● On February 6, 2025, completed IPO at $4.00 per share with gross proceeds of approximately $5.7 million, including partial exercise of over-allotment. ● Announced the appointment of former Assistant Commissioner of the Chicago Department of Public Health, Christopher Shields, as Senior Vice President, Emergency Preparedness & Response/Government Affairs. ● Requested by the State of Texas Department of Health and Human Services to be on standby in readiness to assi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42451 TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Island ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42451 TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Island ...

Financial Performance - Total revenue for Q1 2025 was $40.169 million, a decrease of 10.4% from $45.052 million in Q1 2024[10] - Net loss attributable to Reading International, Inc. for Q1 2025 was $4.752 million, compared to a net loss of $13.228 million in Q1 2024, representing a 64.1% improvement[10] - Operating income for Q1 2025 was a loss of $6.891 million, slightly improved from a loss of $7.531 million in Q1 2024[10] - The company reported a comprehensive loss of $4.301 million for Q1 2025, compared to a comprehensive loss of $15.768 million in Q1 2024, indicating a significant reduction in losses[12] - Total revenue for the three months ended March 31, 2025, was $4,845,000, a decrease of 1.8% compared to $4,933,000 for the same period in 2024[40] - The company reported a net loss attributable to Reading International, Inc. of $4,752,000 for the three months ended March 31, 2025, compared to a net loss of $13,228,000 in the same period of 2024[46] - Basic and diluted earnings per share for Q1 2025 were both $(0.21), an improvement from $(0.59) in Q1 2024[46] Assets and Liabilities - Cash and cash equivalents decreased to $5.911 million as of March 31, 2025, down from $12.347 million at the end of 2024[9] - Total assets decreased to $440.969 million as of March 31, 2025, from $471.011 million at the end of 2024, a decline of 6.4%[9] - Total liabilities decreased to $449.649 million as of March 31, 2025, down from $475.801 million at the end of 2024, a reduction of 5.5%[9] - The company has $53.7 million of debt due within the next twelve months, with a negative working capital of $108.7 million[18] - Total borrowings as of March 31, 2025, amounted to $186.6 million, down from $201.8 million as of December 31, 2024[71] - The current portion of debt decreased to $53.7 million as of March 31, 2025, from $69.2 million as of December 31, 2024[76] - The company's debt-to-equity ratio was (21.50) as of March 31, 2025, indicating a significant increase in leverage compared to (42.32) in 2024[200] - Working capital deficit was reported at $108.7 million as of March 31, 2025, worsening from a deficit of $104.6 million in 2024[200] Cash Flow and Financing Activities - Cash used in operating activities increased by $4.9 million to $7.7 million in Q1 2025, compared to $2.8 million in Q1 2024[197] - Cash provided by investing activities was $17.9 million in Q1 2025, significantly higher than $7.6 million in Q1 2024, due to proceeds from the sale of Wellington property assets[198] - Cash used in financing activities increased by $5.6 million to $16.9 million in Q1 2025, compared to the same period in 2024, driven by higher loan paydowns[199] - The company sold its Wellington property assets for NZ$38.0 million in January 2025, using proceeds to repay loans[192] Real Estate and Asset Management - The company intends to raise liquidity through real estate asset monetization, having successfully sold eight property assets since 2021[22] - The company is under an unconditional contract to sell its Cannon Park property for AU$32.0 million, expected to close on May 21, 2025[21] - The company has monetized several property assets to improve liquidity, including the sale of its Courtenay Central cinema with a long-term leaseback agreement[161] - The company has paused real estate development projects to bolster liquidity, focusing on improvements to existing cinemas instead[136] - The company has entered into an agreement to lease a newly redeveloped 10-screen cinema in Wellington, New Zealand, following the sale of its properties in the region for NZ$38.0 million[168] Cinema Operations - The cinema exhibition segment generated $36.4 million in revenue for the three months ended March 31, 2025, down from $41.3 million in the same period in 2024[37] - The total operating expense for the cinema segment was $40.9 million for the three months ended March 31, 2025, compared to $45.4 million in the same period in 2024[37] - The company recorded a segment operating loss of $4.5 million in the cinema segment for the three months ended March 31, 2025, compared to a loss of $4.2 million in the same period in 2024[37] - The cinema business performance in Q1 2025 was weaker than anticipated, with notable films underperforming compared to industry expectations[121] - The cinema segment operating loss increased by $0.3 million to $4.5 million, attributed to decreased revenue from lower attendance[181] - The cinema segment is expected to benefit from a strong film lineup in 2025, including titles like Lilo & Stitch and Mission Impossible – The Final Reckoning[129] Cost Management and Efficiency - The company has been renegotiating leases to reduce occupancy costs or convert fixed rent to percentage rent, aligning interests with landlords[124] - The company reduced future insurance costs by approximately $1.3 million for the remainder of 2025 through renegotiated supplier contracts[125] - Total operating expenses decreased to $1,955,000 for the three months ended March 31, 2025, down 12.5% from $2,235,000 in the prior year[40] - Depreciation, amortization, and general administrative expenses decreased by 28% to $1.3 million in Q1 2025, compared to $1.8 million in Q1 2024[185] Legal and Regulatory Matters - The company has accrued estimates of probable and estimable losses related to ongoing legal proceedings, although it does not expect these to have a material adverse effect on its business[92] - The company does not currently believe that its exposure under applicable environmental laws is material in amount, despite historical involvement in operations that may have environmental implications[93] Market Conditions and Future Outlook - Management believes that improvements in film releases will enhance patronage and operating revenue, although attendance levels remain uncertain[20] - The company is optimistic about the cinema industry's long-term prospects, citing upcoming high-quality film releases and strong audience attendance for select films[123]

Financial Performance - Total revenue for Q1 2025 was $40.169 million, a decrease of 10.4% from $45.052 million in Q1 2024[10] - Net loss attributable to Reading International, Inc. for Q1 2025 was $4.752 million, compared to a net loss of $13.228 million in Q1 2024, representing a 64.1% improvement[10] - Operating income for Q1 2025 was a loss of $6.891 million, slightly improved from a loss of $7.531 million in Q1 2024[10] - The company reported a comprehensive loss of $4.301 million for Q1 2025, compared to a comprehensive loss of $15.768 million in Q1 2024, indicating a significant reduction in losses[12] - Total segment revenue was $41.249 million, down from $46.204 million in the same period of 2024, reflecting a decrease of approximately 10.5%[37] - The cinema exhibition segment reported a revenue of $36.404 million for the three months ended March 31, 2025, compared to $41.271 million for the same period in 2024, a decline of about 12%[39] - Total revenue for the quarter ended March 31, 2025, decreased by $4.9 million to $40.2 million, a decline of 11% compared to the same period in 2024[174] - Cinema exhibition revenue dropped by $4.9 million to $36.4 million, a decrease of 12% year-over-year, primarily due to lower attendance and cinema closures[180] Assets and Liabilities - Cash and cash equivalents decreased to $5.911 million as of March 31, 2025, down from $12.347 million at the end of 2024[9] - Total assets decreased to $440.969 million as of March 31, 2025, from $471.011 million at the end of 2024, a decline of 6.4%[9] - Total liabilities decreased to $449.649 million as of March 31, 2025, down from $475.801 million at the end of 2024, a reduction of 5.5%[9] - The company has $53.7 million of debt due within the next twelve months, with a negative working capital of $108.7 million[18] - Total borrowings as of March 31, 2025, amounted to $186.6 million, down from $201.8 million as of December 31, 2024[76] - The current portion of debt decreased to $53.7 million as of March 31, 2025, from $69.2 million as of December 31, 2024[76] - The company's debt-to-equity ratio was (21.50) as of March 31, 2025, a significant increase from (42.32) in 2024[200] - Working capital deficit was reported at $108.7 million as of March 31, 2025, compared to $104.6 million in 2024[200] Cash Flow and Financing Activities - Cash used in operating activities increased by $4.9 million to $7.7 million in Q1 2025, compared to $2.8 million in Q1 2024[197] - Cash provided by investing activities was $17.9 million in Q1 2025, significantly higher than $7.6 million in Q1 2024, due to proceeds from the sale of Wellington property assets[198] - Cash used in financing activities increased by $5.6 million to $16.9 million in Q1 2025, compared to the same period in 2024, driven by higher loan paydowns[199] - The company has $53.7 million in debt coming due in the next 12 months, with ongoing efforts to manage liquidity and defer capital expenditures[191] Real Estate and Asset Management - The company intends to raise liquidity through real estate asset monetization, having successfully sold eight property assets since 2021[22] - The company is under an unconditional contract to sell its Cannon Park property for AU$32.0 million, expected to close on May 21, 2025[21] - The company monetized its properties in Wellington, New Zealand for $21.5 million in Q1 2025, contributing to liquidity[51] - The gain on the sale of the Wellington property was $6,566,000 after direct costs[54] - The company sold its Wellington property assets for NZ$38.0 million in January 2025, using proceeds to repay loans[192] - The company has paused real estate development projects to bolster liquidity, focusing on improvements to existing cinemas instead[136] Operating Expenses and Cost Management - Total operating expenses decreased to $1,955,000 in Q1 2025 from $2,235,000 in Q1 2024, reflecting a reduction of 12.5%[40] - The total operating expense for the cinema segment was $40.879 million for the three months ended March 31, 2025, compared to $45.436 million in the same period of 2024, a decrease of approximately 10.5%[37] - Operating expenses for the quarter decreased by $4.2 million to $37.7 million, reflecting lower costs across all regions[182] - The cinema segment operating loss increased by $0.3 million to $4.5 million, driven by decreased revenue from lower attendance[181] Strategic Initiatives and Future Outlook - The management believes that improvements in film releases will enhance patronage and operating revenue, although attendance levels remain uncertain[20] - The cinema industry is expected to benefit from a strong movie release schedule from 2025 to 2027, including high-quality films like Superman and Jurassic World: Rebirth[123] - The cinema segment is expected to benefit from notable movie releases in 2025, including "Mission: Impossible – The Final Reckoning" and "Avatar: Fire and Ash" which are anticipated to drive audience attendance[129] - The company is actively pursuing liquor licenses to enhance Food and Beverage offerings across its cinema circuits in the U.S., Australia, and New Zealand[133] Stock and Equity - Basic and diluted earnings per share for Q1 2025 were both $(0.21), compared to $(0.59) in Q1 2024[46] - The company’s total stockholders' equity decreased from $(4,790,000) at January 1, 2025, to $(8,680,000) at March 31, 2025[97] - The company has accrued estimates of probable and estimable losses related to ongoing legal proceedings, although it does not expect these to have a material adverse effect on its business[92] Miscellaneous - The average exchange rate for the Australian Dollar was 0.6277 for the quarter ended March 31, 2025, compared to 0.6524 for the same quarter in 2024, indicating a strengthening of the USD[44] - The company recorded no impairment charges for the first three months of 2025, despite lower revenues and operating income compared to the same period in 2024[25] - The company has liquor licenses in 100% of its U.S. cinemas, 86% in Australia, and 38% in New Zealand, with ongoing efforts to increase licensing in New Zealand[158]

Financial Performance - Total revenue for the three months ended March 31, 2025, was $934,304, an increase of 20% compared to $779,756 for the same period in 2024[199]. - Products revenue increased by 19% to $565,551, while services revenue rose by 22% to $267,304, and grants increased by 22% to $101,449[199]. - Operating loss decreased by 23% to $5,586,614 for the three months ended March 31, 2025, compared to $7,247,375 for the same period in 2024[199]. - Net loss for the three months ended March 31, 2025, was $6,878,601, a 2% increase from $6,728,737 in the same period in 2024[199]. Expenses - Research and development expenses decreased by 44% to $883,772 for the three months ended March 31, 2025, down from $1,589,577 in the prior year[205]. - Selling, general and administrative expenses decreased by 14% to $5,075,902 for the three months ended March 31, 2025, compared to $5,928,110 in 2024[203]. Cash Flow and Debt - The cash used in operations was $1.8 million for the three months ended March 31, 2025, compared to $15.7 million and $21.3 million for the years ended December 31, 2024, and 2023, respectively[212]. - Net cash used in operating activities decreased by $2.9 million to $1.8 million for the three months ended March 31, 2025, compared to $4.7 million for the same period in 2024[225]. - Net cash provided for financing activities was $2.6 million for the three months ended March 31, 2025, compared to $8.5 million for the same period in 2024[227]. - The total outstanding principal balance of debt as of March 31, 2025, was $4,967,360, down from $5,572,001 as of December 31, 2024[218]. - The company entered into Term Loans totaling $3.75 million with a weighted average interest rate of 2.96% and 2.16% for different maturities[216]. - Interest expense paid on the Term Loan for the three months ended March 31, 2025, was $363,042, with no interest expense for the same period in 2024[216]. Future Outlook - Estimated backlog as of March 31, 2025, was $19.7 million, expected to be recognized as revenue from 2025 through 2026[195]. - The company plans to allocate up to 30% of excess cash towards bitcoin purchases as part of its treasury management program[196]. - The company expects to implement its bitcoin and digital asset strategy in the latter half of 2025[197]. - The company plans to fund current operations through debt obligations, increased revenues, and raising additional capital, although future fundraising success is uncertain[213]. Legal Matters - The company has initiated legal action against Rhombus Energy Solutions, Inc. regarding warranty and commissioning obligations related to DC Chargers purchased[223]. Equity and Financial Position - The company had a total equity deficit of $3.2 million and a cash balance of $1.2 million as of March 31, 2025[212]. - As of March 31, 2025, the company incurred operating losses of approximately $5.6 million for the three months ended March 31, 2025, and $20.5 million and $32.1 million for the years ended December 31, 2024, and 2023, respectively[212].